ReCode Therapeutics raised $31 million to advance its pipeline of therapies, including RCT1100, an inhaled mRNA treatment for Primary Ciliary Dyskinesia (PCD), a rare genetic disorder that causes chronic respiratory infections and progressive lung function decline.
